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Abstract 
The identification of genes predisposing individuals for specific diseases has increased 
the value of genetic testing.  Two genes, BRCA1 and BRCA2, have been shown to be significant 
in hereditary breast and ovarian cancers.  Unfortunately, the mutation results of BRCA genetic 
testing are sometimes unclear.  A class of mutations, termed “variants of uncertain significance” 
(VUS), provides inconclusive and unhelpful results in genetic testing because it is unknown 
whether these variants are cancer causing mutations or neutral polymorphisms.  In our study, we 
combined independent variables including tumor loss of heterozygosity, co-occurrence with a 
known deleterious mutation in trans, sequence conservation or splice site analysis, pathological 
data (estrogen receptor, progesterone receptor, and Her2Neu status; tumor grade; and tumor 
histology), and personal cancer history (age of onset and cancer type) to try to classify VUS as 
deleterious or neutral.  This selection of data allows one to assess the pathogenicity of VUS 
without segregation analysis or familial information, which is often unavailable because of 
family absence or unwillingness to undergo genetic testing.  With these independent data 
sources, we used a modified multifactorial approach for each variant to calculate a final 
likelihood score.  We were able to utilize our method with 98% sensitivity and 76% specificity 
on 57 tumor samples from 44 known deleterious variants.  Additionally, we evaluated 56 tumor 
samples from 54 unique classified and unclassified variants.  Among the 33 unclassified VUS, 
we quantified 21 as neutral.  The classification of VUS as deleterious or neutral will aid patient 
care, specifically improving future decision making regarding screening, chemoprevention, 
prophylactic treatment, and familial risk. 
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Introduction 
 Two tumor suppressor genes, BRCA1 and BRCA2, are located on chromosome 17 and 13, 
respectively.  They encode large proteins, which function similarly in DNA damage repair to 
maintain the integrity of the human genome.  Unfortunately, when BRCA1 and BRCA2 are 
mutated, they predispose individuals to a multitude of cancers1.  In fact, women with BRCA1 or 
BRCA2 gene mutations are three to seven times more likely to develop breast cancer than women 
without mutated genes2.  BRCA1 and 2 are also significant in hereditary breast and ovarian 
cancers as the majority (~84%) of hereditary breast and ovarian cancers result from inherited 
mutations in BRCA1 and BRCA23. 
 The high prevalence of BRCA mutations in hereditary cancers has made genetic testing 
an increasingly powerful tool as more than 70,000 individuals worldwide have undergone 
genetic analysis of BRCA1 and BRCA2 to assess their risk for hereditary breast and ovarian 
cancer4.  The number of individuals undergoing testing will continue to grow as clinical genetic 
analysis is increasingly used for diagnosis confirmation and determining prognosis, treatment 
options, and future risk.  Also, technological advances have made testing more accurate and 
economical. 
 The current drawback of genetic testing on BRCA1 and BRCA2, however, is that 
approximately half, over 1500, of the unique BRCA1 and BRCA2 variants detected are “variants 
of uncertain significance” (VUS)5.  These VUS are predominantly missense mutations or splice 
site mutations with unclear biological importance.  Because their effect on protein function is not 
clear, it is not yet known whether these mutations are deleterious or neutral polymorphic 
changes.  Deleterious changes increase cancer risk dramatically, whereas neutral polymorphic 
changes do not seem to increase cancer risk.  Thus, individuals with genetic testing results of 
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VUS are given unhelpful and ambiguous data, whereas results of known deleterious mutations or 
known neutral mutations can appropriately guide potential screening, chemoprevention, or 
prophylactic surgery for patients and families.   
 Because many VUS are only reported in one or two individuals and many individuals do 
not have access to their family history, we have developed a model to assess the clinical 
significance of BRCA1 and BRCA2 VUS independent of familial information.  Specifically, we 
used tumor loss of heterozygosity, co-occurrence with a known deleterious mutation in trans, 
sequence conservation or splice site analysis, pathological data (estrogen receptor, progesterone 
receptor, and Her2Neu status; tumor grade; and tumor histology), and personal cancer history 
(age of onset and cancer type) to try to classify VUS as deleterious or neutral.   
 Using these tools to analyze VUS, we developed four BRCA VUS classification models 
to assess 57 tumors with known deleterious BRCA mutations and 56 tumors with known neutral 
or unclassified BRCA variants.  Four models were needed because BRCA1 and BRCA2 have 
different pathological characteristics, as do BRCA breast and ovarian cancers.
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Materials and Methods 
Human Samples 
The proposed studies were approved by local institutional review boards, and all 
participants signed informed consent forms.  Paired normal and tumor tissue samples were 
collected through one of three sources: The Ohio State University Comprehensive Cancer Center 
(CCC) Clinical Cancer Genetics program, Fergus Couch at Mayo Clinic, or The University of 
California, San Francisco (UCSF) Familial Risk Shared Resource.  Inclusion into the study 
required a diagnosis of breast or ovarian cancer, source of normal and tumor DNA, and a BRCA 
testing report documenting a BRCA1 and/or BRCA2 known deleterious mutation, known neutral 
mutation, or VUS.  A pathologist analyzed hematoxylin and eosin (H&E) stained tumor sections, 
and areas of the section containing >70% tumor cells were micro dissected from 10μM sections 
or were cored (1.6 or 2.0 mm).  Normal DNA was isolated from blood, histologically normal 
breast tissue from tumor margins, or samples without tumor contamination.  Lymphoblastoid cell 
lines were established from a subset of participants, also. 
Genomic DNA was isolated from tissue samples by removal of paraffin with xylene and 
ethanol washes.  Protein was degraded by proteinase K treatment (30 mg/ml for 48 hours at 
55˚C) in nucleic acid lysis buffer (10 mM Tris, 400 mM NaCl, 2 mM EDTA, and 0.7% SDS).  
DNA samples were then phenol/chloroform extracted and ethanol precipitated. 
 
Loss of Heterozygosity (LOH) 
 Restriction fragment length polymorphism (RFLP) studies and sequence analysis were 
used to conduct allele specific LOH analysis.  We designed forward and reverse primers that 
flanked each specific sequence change (Table 1).  The specified region was amplified by 
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polymerase chain reaction (PCR) for forty cycles (15mM MgCl2 (10x PCR Buffer), 5x Q, 1 unit 
Taq polymerase, 10 ng DNA template, 10 mg forward and reverse primer, and dH2O per 20 μL 
PCR reaction) (Qiagen).  For mutations and variants altering a restriction endonuclease site, the 
PCR products were digested with the corresponding endonuclease, separated on a 1.5% agarose, 
ethidium bromide stained gel and visualized under UV light (Figure 1).  For mutations and 
variants resulting in deletion of ≥20 base pairs (bp), the PCR products were visualized on a 1.5% 
agarose, ethidium bromide stained gel without further treatment.  Finally, for mutations and 
variants not fitting either of the above criteria, the PCR products were treated with ExoSap-It 
(USB) and sequenced (OSUCCC Nucleic Acid Shared Resource) (Figures 2,3).  Sequences of 
control, participant normal, and participant tumor DNA were analyzed in the forward and reverse 
directions. 
 
Promoter Methylation 
 Mutations and variants not showing definitive LOH were analyzed for putative promoter 
methylation.  We methylated wildtype control DNA in vitro at 37°C for 4 hours (10 μg DNA, 30 
units SSsI (CpG methyltransferase), 200x SAM (S-adenosylmethionine), 10x NEB Buffer #2, 
and dH2O per 300 μl reaction) with replenishment of the methyl donor (200x SAM and 2 units 
SSsI) at 2 hours (New England Bio Labs).  Following methylation, the methylated control DNA 
was phenol/chloroform extracted and ethanol precipitated.  Tumor, methylated control, and 
unmethylated control DNA (500 ng) were bisulfite treated (EZ DNA methylation kit, Zymo 
Genetics).  Methylated-bisulfite treated (BST) control, unmethylated-BST control, and non-BST 
control DNA served as controls.  Bisulfite treated samples and control DNA were PCR amplified 
for forty cycles using previously published primers for methylation specific PCR of BRCA1 and 
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BRCA2 promoter regions6,7.  PCR products (BRCA1 UM – 86 bp, BRCA1 M – 182 bp, BRCA2 
UM – 145 bp, and BRCA2 M – 180 bp) were then visualized on a 1.5% agarose, ethidium 
bromide stained gel and visualized under UV light for the presence or absence of methylation. 
 
Co-occurrence with a Deleterious Mutation 
 Given that homozygous BRCA1 and BRCA2 deleterious mutations are lethal or result in 
extreme phenotypes, the occurrence of a deleterious mutation in trans with a VUS suggests the 
VUS is neutral8.  We referred to mutation reports and published data to determine if VUS had 
been observed in co-occurrence with a known deleterious mutation.  The odds of two BRCA1 
and BRCA2 deleterious mutations occurring in trans are 0.0001 and 0.001, respectively3.   
 
Evolutionary Sequence Conservation 
 Missense changes of possible functional relevance were analyzed with alignment-
Grantham variation, Grantham deviation (A-GVGD) to quantify their significance 
(http://agvgd.iarc.fr/alignments.php)8,9.  A-GVGD places each missense mutation into a 
probability class based on evolutionary conservation and properties of the amino acid.  Class 0 
variants are expected to be neutral, and Class 65 variants are expected to be vital to protein 
function.  Using data from Myriad Genetic Laboratories, published literature10, and Dr. Toland’s 
personal communication with S. Tavtiglian, we calculated odds of being deleterious for each A-
GVGD class (Table 3). 
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Splice Site Analysis 
 Lymphoblastoid cell lines were established from a subset of individuals with splicing 
mutations or variants.  RNA was isolated (RNeasy Mini Kit, Qiagen) from the cell lines and 
reverse transcribed (1 μg) into cDNA (iScriptTM, BioRad).  We amplified the cDNA with primer 
sets on the two flanking exons and a third primer set on the causal exon.  We accessed atypical 
splicing by comparing RT-PCR product of the tumor cell line and wildtype controls.  We 
determined abnormal splicing when bands of the tumor sample differed from bands visualized in 
eleven wildtype cDNA controls.  We verified abnormal splicing with sequencing. 
 
Identification of Study Criteria for Models 
 Under the assumption that BRCA1 and BRCA2 mutation positive breast and ovarian 
tumors are characteristically distinct from BRCA1 and BRCA2 mutation negative tumors, we 
identified tumor characteristics to differentiate deleterious and neutral BRCA variants from 
published literature (Table 2)3,13-51.  We specified our list to characteristics that are routinely 
available from pathology and mutation reports in order to make our models more applicable to a 
wide range of individuals.  Additionally, we formed four models, one for each gene and tumor 
type, because the characteristics for classifying VUS varied between breast and ovarian tumors 
and between BRCA1 and BRCA2.  From the frequencies of tumor characteristics and 
experimental methods, we created likelihood odds for our models (Table 3).  Then, we collected 
histopathological and clinical data from medical records and mutation reports from all of our 
samples for our targeted characteristics (Tables 4 and 5). 
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Statistical Analysis 
In order to calculate the likelihood of pathogenicity for each variant, we used a modified 
multifactorial approach that combined the odds of causation of each independent variable3,10-12.  
The likelihood odds for each variable were taken from published odds or derived from 
frequencies reported in published literature (Table 2), with the exception of truncating mutations 
and splice site mutations.  We determined odds of 1000:1 in favor of deleterious if splicing 
defects or truncating mutations were found and odds of 1:100 if splicing defects were not found.  
The likelihood odds for each independent variable (Table 3) were combined to formulate the 
overall odds of pathogenicity.  For our ultimate classification, we followed the standard of 
previous work and applied the cut-off of 1000:1 in favor of deleterious and 100:1 in favor of 
neutral3,10. 
To calculate sensitivity we compared our results with known or previously predicted 
deleterious variants, and to calculate specificity we compared our results with previously 
predicted neutral variants. 
Finally, we computed odds with and without LOH because the frequency of LOH in 
BRCA neutral variants is still uncertain and LOH data may not be easily attainable in all 
assessments of VUS.  Thus, we categorized variants as suspected neutral or suspected deleterious 
if the final odds were only significant with LOH data included.
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Results 
Loss of Heterozygosity (LOH) 
 LOH occurs more frequently in BRCA mutation positive tumors than BRCA mutation 
negative tumors (Table 2), and thus, the presence of BRCA1 or BRCA2 LOH has previously been 
used to assess the pathogenicity of VUS3,20,21,23,52. 
 For our known deleterious variants, we observed LOH of the BRCA1 wildtype allele in 
85% (28/33) of breast tumors, 100% (3/3) of ovarian tumors, and LOH of the BRCA1 mutant 
allele in 3% (1/33) of breast tumors (Tables 4 and 5).  We observed LOH of the BRCA2 wildtype 
allele in 63% (10/16) of breast tumors, 25% (1/4) of ovarian tumors, and LOH of the BRCA2 
mutant allele in 6% (1/16) of breast tumors (Tables 4 and 5).  The BRCA1 frequencies follow 
closely with published rates, but the BRCA2 frequencies are slightly lower than other published 
rates3.  The observed frequency of LOH of the mutant allele was also higher than expected 
because published literature proposes an approximate 1% frequency of LOH of the mutant allele 
for deleterious mutations3,20,21,23,52. 
 For our BRCA1 VUS, we observed LOH of the wildtype allele in 32% (7/22) of tumors, 
LOH of the variant allele in 14% (3/22), and 55% (12/22) showed no imbalance.  For BRCA2 
VUS, we observed LOH of the wildtype allele in 26% (9/35) of tumors, LOH of the variant 
allele in 23% (8/35), and 51% (18/35) showed no imbalance (Tables 4 and 5). 
 
Promoter Methylation 
 Promoter Methylation is believed to be another mechanism that can inactivate tumor-
suppressor genes53,54.  In the absence of LOH, we hypothesized that we would detect promoter 
methylation in a subset of tumors.  Our results, however, did not support this hypothesis because 
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only 3/13 BRCA1 variants (23%) and 0/20 BRCA2 variants (0%) showed possible methylation.  
Of the three BRCA1 variants showing possible methylation, the bands seen for unmethylated 
DNA were much stronger than the bands showing methylation (Examples of three unmethylated 
BRCA1 variants in Figure 4).  Our results more clearly indicate, however, that promoter 
methylation plays a very small role in inactivation of BRCA2 ( Examples of BRCA2 methylation 
analysis Figures 5,6).  Because of the low frequencies and non-definitive results, we did not 
include promoter hypermethylation in our predictive models. 
 
Co-occurrence with a Deleterious Mutation 
 Through mutation reports and published literature3, we discovered three BRCA1 (V772A, 
Y856H, and P334L) and two BRCA2 (S384F and D1420Y) known neutral variants or VUS that 
were found to co-occur in trans with a known deleterious variant (Tables 4-7).  Subsequently, 
our predictive models classified all five variants as neutral.  
 
Evolutionary Sequence Conservation 
 We used A-GVGD, to quantify the pathogenicity of missense mutations in BRCA1 and 
BRCA2 using our calculated odds for each A-GVGD class (Table 3).  For our BRCA1 missense 
substitutions, A-GVGD categorized 1/16 (6%) as C65; 1/16 (6%) as C55, C45, or C35; 0/16 
(0%) as C25 or C15; and 14/16 (88%) as C0.  For our BRCA2 missense substitutions, A-GVGD 
categorized 0/33 (0%) as C65; 0/33 (0%) as C55, C45, or C35; 6/33 (18%) as C25 or C15; and 
27/33 (82%) as C0.  Thus, all missense substitutions, except BRCA1 C61G and L1764P, were 
placed in A-GVGD classes that favor neutrality.  Also, C61G was previously classified as 
deleterious, in addition to our overall deleterious classification. 
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Splice Site Analysis 
 From a subset of individuals with intronic sequence changes, we received lymphoblastoid 
cell lines.  We conducted splice site analysis on four different cell lines with splicing VUS and 
one cell line with a known deleterious splice mutation.  With eleven controls, none of the 
splicing VUS (BRCA1: IVS2-14C>T and IVS20-14C>G; BRCA2: IVS8-12delTA and 
IVS23+9C>T) showed splicing defects, but the known deleterious splice mutation (BRCA1: 
IVS5-11G>T) showed a splice defect (Figures 7,8).  From published literature55 and ESEfinder, 
we determined that two additional BRCA1 intronic sequence changes (IVS4-1G>T and 
IVS13+1G>A) showed splicing defects. 
 
Classification 
 We created four models using allele specific LOH, co-occurrence with a known 
deleterious mutation in trans, sequence conservation or splice site analysis, pathological data 
(estrogen receptor, progesterone receptor, and Her2Neu status; tumor grade; and tumor 
histology), and personal cancer history (age of onset and cancer type) to classify BRCA sequence 
changes (Tables 6,7).  We assessed 57 tumors with 44 known BRCA mutations and 56 tumors 
with 54 known BRCA neutral mutations or VUS using these four models.  When we had multiple 
tumor samples for the same variant, we combined independent variables for classification.  We 
classified 43/44 known deleterious mutations correctly (98% sensitivity), and we classified 16/21 
mutations neutral that others have also predicted to be neutral (76% specificity)3,8,10,12,55-60.  Of 
our VUS, 21/33 (64%) were classified as neutral. 
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Discussion 
 We constructed four predictive models using allele specific LOH, co-occurrence with a 
known deleterious mutation in trans, sequence conservation or splice site analysis, pathological 
data (estrogen receptor, progesterone receptor, and Her2Neu status; tumor grade; and tumor 
histology), and personal cancer history (age of onset and cancer type) to classify BRCA sequence 
changes (Tables 4-7).  We assessed 57 tumors with 44 known BRCA mutations and 56 tumors 
with 54 known BRCA neutral mutations or VUS using these four models. We classified 43/44 
known deleterious mutations correctly (98% sensitivity), and we classified 16/21 mutations 
neutral that others have also predicted to be neutral (76% specificity).  The remainder of known 
mutations were classified as uncertain; no known mutations were incorrectly predicted to be 
deleterious or neutral.  Of our VUS, 21/33 (64%) were classified as neutral (Table 8) with our 
four predictive models. 
 Our experimental studies also included the analysis of hypermethylation in the promoter 
regions of BRCA1 and BRCA2.  Our findings, however, were not definitively clear.  For BRCA1, 
3/13 variants (23%) showed possible promoter hypermethylation, but the conclusions are not 
definitive as the bands seen for unmethylated DNA were much stronger than the bands showing 
methylation.  Thus, it is possible that these three variants had partial methylation in their 
promoter region, which may or may not inactivate BRCA1.   For BRCA2, we are more confident 
that 0/20 variants (0%) showed methylation, and promoter hypermethylation plays a minor role 
in BRCA2 inactivation.  We omitted methylation data from the models in order to maintain our 
confidence in the models.   
 Additionally, our predictive models allow the assessment of pathogenicity based on 
characteristics, with the exception of LOH, routinely found in pathology reports, mutation 
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reports, published literature, and online.  Our models allow characterization of VUS independent 
of familial information, which is often unavailable.  In the future, similarly fashioned predictive 
models can be applied beyond BRCA1 and BRCA2 to further understand other disease 
predisposing genes. 
 Finally, the classification of VUS as neutral or deleterious will advance patient care by 
improving the value of genetic testing.  More accurate genetic testing results can be used to 
confirm diagnosis and assess prognosis, screening options, preventative measures, and familial 
risk.
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Table 1: Variant Specific Primer Sequences and Annealing Temperatures 
Gene Sequence Change Forward Primer (5’ > 3’) Reverse Primer (5’ > 3’) 
Annealing 
Temp. (˚C)
BRCA1 1135insA GCC AGC TCA TTA CAG CAT GAG AAC  TCT CTG AGC ATG GCA GTT TCT G 54 
BRCA1 1240delC TGT AAT GAT AGG CGG ACT CCC A CCC ATC ATG TGA GTC ATC AGA ACC 56 
BRCA1 1294del40 AGC AGA AAC TGC CAT GCT CAG AGA TTC ATC TAC CTC ATT TAG AAC GTG CA 56 
BRCA1 1547del10 GAG GTA GAT GAA TAT TCT GGT TCT TCA GAG GGG ACG CTC TTG TAT TAT CTG TGG 56 
BRCA1 1623del5 AAC CTA TCG GAA GAA GGC AAG C CTC CGT TTG GTT AGT TCC CTG A 56 
BRCA1 1675delA AAC CTA TCG GAA GAA GGC AAG C CAT CAC TTG ACC ATT CTG CTC C 56 
BRCA1 1793delA TCA GGG AAC TAA CCA AAC GG CTT TTT AGG TGC TTT TGA ATT GT 60 
BRCA1 187delAG TGT GTT AAA GTT CAT TGG AAC A CAT AGG AAT CCC AAA TTA ATA CA 56 
BRCA1 262delT GCT CTT AAG GGC AGT TGT GAG A TGG TTG CTT CCA ACC TAG CAT C 56 
BRCA1 2530delAG CCA AAG ATC TCA TGT TAA GTG GAG AAA GGG GGA ACA ACC ATG AAT TAG TCC CTT GG 56 
BRCA1 2553delC CCT GGT ACT GAT TAT GGC ACT CAG GA CTA TGC TTG TTT CCC GAC TGT GGT 58 
BRCA1 2576delC CTG GTA CTG ATT ATG GCA CTC AGG CTA TGC TTG TTT CCC GAC TGT G 56 
BRCA1 2800delAA CCA CAG TCG GGA AAC AAG CAT AGA CAC AGG AAA GCC TGC AGT GAT A 56 
BRCA1 3118delA CAT CTC AGT TCA GAG GCA ACG A GCC CAC TTC ATT AGT ACT GGA ACC 56 
BRCA1 3600del11 TTT CAG ATA ACT TAG AAC AGC CTA TGG GA ATG GGT GAA AGG GCT AGG ACT C 56 
BRCA1 5382insC AGT CAG AGG AGA TGT GGT CAA TGG GTG GTT GGG ATG GAA GAG TGA A 56 
BRCA1 E143X CCA AAG TAT GGG CTA CAG AAA CCG GTG CCT GTA ATC CCA GCT ACT AAG 62 
BRCA1 Q563X TAC ATC AGG CCT TCA TCC TGA G GAA GAC TTC CTC CTC AGC CTA TTC 56 
BRCA1 S868X GAC ACA GAA GGC TTT AAG TAT CCA TT TTC TTT AAG GAC CCA GAG TGG GCA 58 
BRCA1 Q1408X GCT AGA ACT TGT AGT TCC ATA CTA GGT GAT GGA AGG GTA GCT GTT AGA AGG 56 
BRCA1 C61G ATG GCT CTT AAG GGC AGT TGT G GTG GTT GCT TCC AAC CTA GCA T 56 
BRCA1 IVS4-1 G>T GCT CTT AAG GGC AGT TGT GAG A CTG TGG TTG CTT CCA ACC TAG CAT 56 
BRCA1 IVS13+1 G>A CCT TCT AAC AGC TAC CCT TCC ATC GGC TCC ATA ATT ACC CAT GTG CTG 58 
BRCA1 IVS15+1 G>A GGG AGT CTT CAG AAT AGA AAC TAC CCA CCA GAA TAT CTT TAT GTA GGA TTC AGA G 56 
BRCA1 IVS5-11 T>G CTA AAT CAC TGC CAT CAC ACG G GCA CTT GAG TGT CAT TCT TGG G 56 
BRCA1 E597K TAC ATC AGG CCT TCA TCC TGA G GAA GAC TTC CTC CTC AGC CTA TTC 56 
BRCA1 E736A CAT GAC AGC GAT ACT TTC CCA GAG CCT GAG TGC CAT AAT CAG TAC CAG 56 
BRCA1 I1275V TGA GGA TGA AGA GCT TCC CTG CTT GGT GAT GTT CCT GAG ATG CCT TTG C 56 
BRCA1 IVS12+10G>C CCA GTC CTG CCA ATG AGA AGA A CTG AAT GCA AAG GAC ACC ACA C 56 
BRCA1 IVS20-14C>G TCC CTG GGA AGT AGC AGC AGA AAT TGT AAG ACA AAG GCT GGT GCT GGA 60 
BRCA1 IVS2-14C>T TTC TCA GTT CCT GAC ACA GCA G GGT GTT TCC TGG GTT ATG AAG GAC 56 
BRCA1 IVS2-6T>C TTC TCA GTT CCT GAC ACA GCA G GGT GTT TCC TGG GTT ATG AAG GAC 56 
BRCA1 K1109N GCA GAA CTA GGT AGA AAC AGA GGG CTA ACA GGT CAT CAG GTG TCT CAG 56 
BRCA1 L1764P TCC CTG GGA AGT AGC AGC AGA AAT TGT AAG ACA AAG GCT GGT GCT GGA 60 
BRCA1 P1776H TCC CTG GGA AGT AGC AGC AGA AAT TGT AAG ACA AAG GCT GGT GCT GGA 60 
BRCA1 P334H GCC AGC TCA TTA CAG CAT GAG AAC CCC ATC ATG TGA GTC ATC AGA ACC 56 
BRCA1 P334L GCC AGC TCA TTA CAG CAT GAG AAC CCC ATC ATG TGA GTC ATC AGA ACC 56 
BRCA1 S127N GAG CAT ACA TAG GGT TTC TCT TGG T TTC GGG TTC ACT CTG TAG AAG TC 56 
BRCA1 V1247I CCT GCT TCC AAC ACT TGT TA TGA TGT TCC TGA GAT GCC TTT 56 
BRCA1 V1804D CTA CTT AGG AGG CTG AGA TGG AAG CCC ATA TAG CAC AGG TAC ATG CAG 56 
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BRCA1 V772A CAT GAC AGC GAT ACT TTC CCA GAG CTT CCC TAG AGT GCT AAC TTC CAG 56 
BRCA1 Y856H GAC TAA TTC ATG GTT GTT CCA CAC ATT CAA AAG TGA CTT TTG G 61 
BRCA1 P1637L CAA CCT CTG CAT TGA AAG TTC CC GGA TAC ACT CAC AAA TTC TTC TGG G 56 
BRCA1 T1310K GTT GCT ACC GAG TGT CTG TCT AAG GCC CGT TCC TCT TTC TTC ATC ATC 56 
BRCA2 2041delA AGC CAC CAC CAC ACA GAA T GAC AGA GGT ACC TGA ATC AGC A 56 
BRCA2 3036del4 GAC TTG ACT TGT GTA AAC GAA CCC CCT AAG AGT CCT GCC CAT TTG TTC 56 
BRCA2 3972del4 GCA GCA AGC AAT TTG AAG GTA CAG AAG TGC CAG TAG TCA TTT CAA 60 
BRCA2 4206ins4 GTC ATG ATT CTG TCG TTT CAA TG GCT GAT CAG TAA ATA GCA AGT CCG 56 
BRCA2 4361del4 CTG CTG CCA GTA GAA ATT CTC ATA AC GCT TCT TGA GCT TTC GCA ACT TCC 56 
BRCA2 6174delT CGA GGC ATT GGA TGA TTC AGA G GAG CTG GTC TGA ATG TTC GTT AC 56 
BRCA2 6307insA CGC AAG ACA AGT GTT TTC TGA A GCT TTC CAC TTG CTG TAC TAA A 58 
BRCA2 6503delTT CTG CTT TCT CTG GAT TTA GTA CAG C GTT TAC ACA GTG CTC TGG GTT TC 56 
BRCA2 7297delCT CAC CAT GTA GCA AAT GAG GGT CTG CTT TGG TTG GTC TGC CTG TAG T 56 
BRCA2 7990del3ins2 CAG CTG TAT ACG TAT GGC GTT TC AAG AGA AGA AAG AGG GAT GAG GG 56 
BRCA2 8765delAG CTC AGG TGA TCC ACT AAT CTC AGC CCT TCA TGT TCT TCA AAT TCC TCC TG 56 
BRCA2 8803delC ATC TCA GCC TCC CAA AGT TCT G CCT TCA TGT TCT TCA AAT TCC TCC TG 62 
BRCA2 9481insA TTT CAG ATT TAC CAG CCA CGG G GCC AAC TGG TAG CTC CAA CTA ATC 56 
BRCA2 Q321X GCT GCA AAG ACC ACA TTG GAA AGT C TGT CAC TTC CAC TCT CAA AGG GCT 56 
BRCA2 S1882X CAC CTG CAT TTA GGA TAG CCA GTG GTG AAT GCG TGC TAC ATT CAT CAT 56 
BRCA2 Y1894X CAC CTG CAT TTA GGA TAG CCA GTG AAC CTT ATG TGA ATG CGT GCT AC 56 
BRCA2 5270delTG GTT TCT ATT GAG ACT GTG GTG CC CTG GTT GAC CAT CAA ATA TTC CTT CTC 56 
BRCA2 A1170V GAA GAA TCA GGA AGT CAG TTT GAA CAG GCC AGC AAA CTT CCG TTT A 56 
BRCA2 A2351G CAC CAT GTA GCA AAT GAG GGT CTG CTT TGG TTG GTC TGC CTG TAG T 56 
BRCA2 D1352Y CTG CTG CCA GTA GAA ATT CTC ATA AC CCA TGA CAT GCT TCT TGA GCT TTC 56 
BRCA2 E2856A GTG GAT GGA GAA GAC ATC ATC TGG CTG TCC CTT GTT GCT ATT CTT TGT C 56 
BRCA2 H1966Y GAA TGT AGC ACG CAT TCA CAT AAG G TGT GAG CTG GTC TGA ATG TTC G 56 
BRCA2 I2285V AGT GGT GTT TTA AAG TGG TCA AAA GGA TCC ACC TGA GGT CAG AAT A 60 
BRCA2 IVS13+5G>C CCT AGG CAC AAT AAA AGA TC CGG GAA GTG TTA ACT TCT TA 56 
BRCA2 IVS23+9C>T GAG CTA ACA TAC AGT TAG CAG CG AGG TCC ACC TCA GAA CAA GAT G 56 
BRCA2 IVS8-12delTA CAC ACT ACT CAG GAT GAC ACA CA CAG AGG ACT TAC CAT GAC TTG CAG 58 
BRCA2 K1434I GGA AGT TGC GAA AGC TCA AGA AG GTC TGT TTC CTC ATA ACT TAG AAT GTC C 56 
BRCA2 L2106P CTG CTT TCT CTG GAT TTA GTA CAG C GTT TAC ACA GTG CTC TGG GTT TC 56 
BRCA2 L929S GAC TTG ACT TGT GTA AAC GAA CCC GAA ATT GGA CCT AAG AGT CCT GCC 56 
BRCA2 M2676T GAT ACG GAA ATT GAT AGA AGC A GCC ACT TTT TGG GTA TCT GC 60 
BRCA2 V1643A GTT TCT ATT GAG ACT GTG GTG CC CTG GTT GAC CAT CAA ATA TTC CTT CTC 56 
BRCA2 N1878K CTT GTG ACT AGC TCT TCA CCC T CAT CCA ATG CCT CGT AAC AAC C 56 
BRCA2 S326R CTA TGA GAA AGG TTG TGA G CAG CGT TTG CTT CAT GGA AA 57 
BRCA2 N517S GCC ACG TAT TTC TAG CCT ACC A GAG TCC TCC TTC TGT GAG CAA A 56 
BRCA2 N588D GTT TGC TCA CAG AAG GAG GAC T GAC AGA GGT ACC TGA ATC AGC A 56 
BRCA2 N987I CAC AGG TGA TAA ACA AGC AAC CC GAA ATT GGA CCT AAG AGT CCT GCC 56 
BRCA2 S1172L CCA TAA TTT AAC ACC TAG CCA AAA GG CCA GCA AAC TTC CGT TTA ATT TC 58 
BRCA2 P1819S GCC AGT ATT GAA GAA TGT TGA AGA TC GTA ACA ACC TGC CAT AAT TTT CGT T 61 
BRCA2 P655R TGT TTA GGT TTA TTG CAT TCT TCT GTG GCA TGA CAG AGA ATC AGC TTC TGG 56 
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BRCA2 M784V CTG CAG CAT GTC ACC CAG TA TCA TAA TTG TTA CCT TTG AGC TTG TCT G 56 
BRCA2 R2034C CGC AAG ACA AGT GTT TTC TGA GCT TTC CAC TTG CTG TAC TAA 58 
BRCA2 R2418G CTA CAG GCA GAC CAA CCA AAG TCT GTT ACA GCT GCT GCT TGA TTG GAG 56 
BRCA2 R2502H TGC CAG AGA TAT ACA GGA TAT GCG CCA TTC CTG CAC TAA TGT GTT CAT 56 
BRCA2 R2973C GAG CAG TTA AGA GCC TTG AA CTA ACT TTA TAC TTT ATC TGG A 58 
BRCA2 D1420Y GGA AGT TGC GAA AGC TCA AGA AG GTC TGT TTC CTC ATA ACT TAG AAT GTC C 56 
BRCA2 S1424C GGA AGT TGC GAA AGC TCA AGA AG GTC TGT TTC CTC ATA ACT TAG AAT GTC C 56 
BRCA2 S2483N TCT TGA ACT CCC GAC CTC AGA T CTT TCA GAG AGA TTC GAG GCA GAG 56 
BRCA2 L2721H AGG GAT GAC ACA GCT GCA AA CTT CAA GAG GTG TAC AGG CAT CAG 56 
BRCA2 S384F TTT CCA TGA AGC AAA CGC TG GGT GAT TCT CTT ATT CTG AAT A 56 
BRCA2 T2681R CGG AAA TTG ATA GAA GCA GAA GAT CGG CTA ACT GGG CCT TAA CAG CAT ACC 56 
BRCA2 T3211K ACT AAA GAC TGT ACT TCA GGG CCG ACA GGA GCC ACA TAA CAA CCA C 58 
BRCA2 Y42C TGA TCT TTA ACT GTT CTG GGT CAC GAG TCA GCC CTT GCT CTT TGA A 56 
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Figure 1: BRCA1 Q563X Restriction Digest of Normal DNA 
(heterozygote), Tumor DNA, and Wildtype Control DNA.  
Hpy188I cleaves wildtype allele into 2 bands (169 and 159 
bp), and is unable to cleave variant (Q563X) allele (324 bp).  
The Tumor DNA has a greater ratio of variant allele compared 
to the Normal DNA (heterozygote).  Thus, there is loss of the 
wildtype allele. 
Figure 2: Sequencing of the 
BRCA2 Y42C variant with 
Normal, Tumor, and Wildtype 
Control DNA.  The Normal 
DNA has a relatively equal 
ratio of wildtype and variant 
alleles.  The Tumor DNA has 
a greater ratio of wildtype 
allele compared to the Normal 
DNA.  Thus, there is loss of 
the variant allele. 
Wildtype: A allele 
Y42C: G allele 
Wildtype: T allele 
L1764P: C allele 
Control 
Normal 
Tumor 
Control 
Figure 3: Sequencing of the 
BRCA1 L1764P variant with 
Normal, Tumor, and 
Wildtype Control DNA.  
The Normal DNA has  a 
relatively equal ratio of 
wildtype and variant alleles.  
The Tumor DNA has a 
greater ratio of variant allele 
compared to the Normal 
DNA.  Thus, there is loss of 
the wildtype allele.
Normal 
Tumor 
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Table 2: Frequency of histopathological characteristics of BRCA1, BRCA2 and sporadic tumors 
Breast Sporadic BRCA1  BRCA2  Ovarian Sporadic BRCA1  BRCA2 
  
BRCA1 Loss 3,16-
21,23-24 
20-40% 
(30%) 
68-100% 
(80%) 
N/A BRCA1 Loss27,29,31-
34 
40-66% 
(40%) 
72-100% 
(90%) 
N/A 
 
BRCA2 Loss 
16,19,20,22,23,25,26 
22-50% 
(30%) 
N/A 38-100% 
(70%) 
BRCA2 Loss27,29-
31,35 
30-42% 
(30%) 
N/A 80-100% 
(80%) 
Medullary45-58 1-3% (1.5%) 11-13% 
(12%) 
N/D Serous29,41-44 29-47% 
(34%) 
40-100% 
(50%) 
39-100% 
(60%) 
Triple Negative36-
40,45 
10-25% 
(16%) 
80% 
(80%) 
N/D Mucinous29,41-44 11-36% 
(17%) 
0-3% (2%) 0-2% 
(1%) 
ER negative 
37,46,47,49-52,55,57,58 
13-37%  
(26%) 
63-90% 
(83%) 
N/D Endometroid29,41-44 5-33% 
(26%) 
N/A 0-29% 
(18%) 
PR Positive37,49,55  58-68% 
(65%) 
16-21% 
(20%) 
N/D Grade 143,44 10-19% 
(13%) 
1-3% (2%) 0-3% 
(3%) 
Her2 
positive36,45,46, 49 
12-35% 
(20%) 
0-3%  
(3%) 
0-3% 
(3%) 
Grade243,44 21-34% 
(31%) 
22%-27% 
(26%) 
13-14% 
(14%) 
Her2 negative 
36,45,46,49,51,55,57 
70-88% 
(80%) 
97-100% 
(97%) 
97-100% 
(97%) 
Grade 343,44 50-55% 
(54%) 
72-75% 
(72%) 
81-87% 
(87%) 
ER+/Grade 150,52 27-42% 
(30%) 
0-2.4% 
(2%) 
5-17% 
(7%) 
Stage 142,43 24% 3-17% 
(17%) 
0-6% 
(6%) 
ER+/Grade 250,52 11-28% 
(27%) 
10-17% 
(10%) 
22-45% 
(41%) 
Stage 242,43 17% 10-16% 
(10%) 
0-6% 
(6%) 
ER+/Grade 350,52 9-17% 
(13%) 
12-28% 
(13%) 
28-30% 
(28%) 
Stage 342,43 40% 69-70% 
(69%) 
82-100% 
(82%) 
ER-/Grade 150,52 3-14% (5%) 0-1% (1%) 1-4% 
(2%) 
Stage 442,43 19% 3-11% 
6% 
0-7% 
5% 
ER-/Grade 250,52 12-13% 
(13%) 
9-13% 
(13%) 
2-17% 
(5%) 
    
ER-/Grade 350,52 12-16% 
(16%) 
62-91% 
(65%) 
9-18% 
(16%) 
    
Grade 1 36-
38,40,45,47-50,52 
18-56% 
(22%) 
0-9% 
(2.5%) 
11-22% 
(17%) 
    
Grade 2 36-
38,40,45,47-50,52 
23-49% 
(42%) 
16-26% 
(23%) 
29-49% 
(43%) 
    
Grade 3 36-
38,40,45,47-50,52 
21-49% 
(36%) 
66-100% 
(71%) 
38-64% 
(47%) 
    
Ranges of frequencies reported in the literature are shown.  Frequency used for weighting is in 
parentheses.   
Abbreviations: ER, estrogen receptor; +, positive staining; - , negative staining; N/A, not applicable 
comparison; N/D, not calculated as the literature suggests no differences from sporadic rates 
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Table 3: Odds for VUS classification 
Breast BRCA1  BRCA2  Ovarian BRCA1 BRCA2 
  
No LOH 0.285 0.428 No LOH 0.167 0.428 
Loss of wildtype 5.26 4.6 Loss of wildtype 4.45 4.6 
Loss of variant3 0.067 0.067 Loss of variant 0.05 0.067 
Medullary  8.0 N/A Serous 1.47 1.76 
ER negative 3.2 N/A Mucinous 0.11 0.06 
Triple negative 5.0 N/A Endometroid N/A 0.69 
ER positive 0.23 N/A Grade 1 0.15 0.23 
ER negative 3.2 N/A Grade 2 N/A 0.45 
PR positive 0.31 N/A Grade 3 1.33 1.61 
PR negative 2.29 N/A Stage 1 0.71 0.25 
Her2 positive 0.15 0.15 Stage 2 0.59 0.35 
Her2 negative 1.2 1.2 Stage 3 1.73 2.05 
ER+/Grade 1 0.067 0.23 Stage 4 0.32 0.26 
ER+/Grade 2 0.37 1.5 Diagnosis >6010 4.6 4.52 
ER+/Grade 3 N/A 2.2 Diagnosis 50-5910 11.8 7.92 
ER-/Grade 1 0.2 0.4 Diagnosis 40-4910 18.0 4.05 
ER-/Grade 2 N/A 0.38 Diagnosis <4010 7.06 0.52 
ER-/Grade 3 4.1 N/A Unconserved domain 0.01 0.01 
Grade 1 0.11 0.77 Conserved C0 0.01 0.01 
Grade 2 0.55 N/A Conserved C15,25 0.41 0.41 
Grade 3 1.97 1.3 Conserved C35,45,55 1.5 1.5 
Diagnosis >6010 1.25 1.55 Conserved C65 4.26 4.26 
Diagnosis 50-5910 1.67 2.07 Splice defect 1000 1000 
Diagnosis 40-4910 3.40 2.89 Not affecting splicing 0.01 0.01 
Diagnosis 30-3910 9.65 4.97 Truncating mutation 1000 1000 
Diagnosis <3010 15.3 4.71 In trans with mutation 0.0001 0.001 
Unconserved domain 0.01 0.01    
Conserved C0 0.01 0.01    
Conserved C15,25 0.41 0.41    
Conserved C35,45,55 1.5 1.5    
Conserved C65 4.26 4.26    
Splice defect 1000 1000    
Not affecting splicing 0.01 0.01    
Truncating mutation 1000 1000    
In trans with mutation 0.0001 0.001    
10Odds for age of diagnosis as previously reported 
Abbreviations: N/A, not applicable as no significant differences identified;  
LOH, loss of heterozygosity; ER, estrogen receptor; +, positive; -, negative;  
Bilateral, bilateral breast cancer; C, align-grantham variation, grantham deviation class.
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Table 4: BRCA1 and BRCA2 breast tumor characteristics 
Sequence Change Sample 
Conserved 
Domain 
A-
GVGD/ 
Class 
 
 
LOH 
Splice 
Defect 
In 
Trans 
Age 
Dx Grade ER PR 
 
 
Her 2
 
 
Histology 
BRCA1 truncating 
1135insA 1463 N/A N/A  WT * N/A  38 3 - - - IDC 
1240delC 0409 N/A N/A WT * N/A 38 2 - - - DCIS 
1294del40 4439 N/A N/A WT * N/A * 4 - - * IDC 
1294del40 127345 N/A N/A WT * N/A 40 3 - - + IDC 
1294del40 78081 N/A N/A WT * N/A 51 1 - - * IDC 
1294del40 169184 N/A N/A WT * N/A 32 * - - - * 
1547del10 21538 N/A N/A WT * N/A 33 3 - - + IDC 
1623del5 71759 N/A N/A WT * N/A 39 2 - - + IDC 
1675delA 10950 N/A N/A WT * N/A 36 3 - - * IDC 
1793delA 12313 N/A N/A WT * N/A 37 3 - - - IDC 
187delAG 45251a** N/A N/A WT * N/A 35 3 - - + IDC 
187delAG 45251b** N/A N/A WT * N/A 36 3 - - - IDC 
187delAG 5042 N/A N/A WT * N/A 35 3 - - - IDC 
2530delAG 458 N/A N/A WT * N/A 30 2 - - - IDC 
2553delC 4724 N/A N/A WT * N/A 27 3 - * * IDC 
2576delC 61933 N/A N/A WT * N/A 58 3 - - - IDC 
2576delC 175158 N/A N/A WT * N/A 47 * + + - IDC 
2800delAA 24042a** N/A N/A WT * N/A 39 3 * * * IDC 
2800delAA 24042b** N/A N/A None * N/A 47 2 - - - IDC 
3118delA 11984 N/A N/A V * N/A  32 3 - - - IDC 
3600del11 34406 N/A N/A WT * N/A 37 2 - - - Unspecified 
5382insC 20758 N/A N/A WT * N/A 61 2 - - * IDC 
E143X 34642 N/A N/A WT * N/A 32 3 - - - IDC 
Q563X 61051 N/A N/A WT * N/A 47 3 + - - IDC 
S868X 176811 N/A N/A None * N/A 74 3 + + - ILC 
Q1408X 34642 N/A N/A None * N/A 29 * - - - Unspecified 
BRCA1 splice defect 
IVS4-1 G>T 2364a** N/A N/A WT Yes54 No 48 3 - - * DCIS, LCIS 
IVS4-1 G>T 2364b** N/A N/A WT Yes54 No 49 1 + + - DCIS, LCIS 
IVS13+1 G>A 98453 N/A N/A None Yes@ No 41 2 - - - IDC 
IVS15+1 G>A 2-112-140 N/A N/A WT Yes@ No * 4 - - * IDC 
IVS5-11 T>G 45949 N/A N/A WT Yes No 59 2 - - - Medullary 
BRCA1 intronic 
IVS12+10G>C 78081 N/A N/A None * No 51 1 - - * IDC 
IVS20-14C>G 168788 N/A N/A None No No 34 3 + + - IDC 
IVS2-14C>T 64703 N/A N/A V No No 44 1 + + - IDC 
IVS2-6T>C 15007 N/A N/A None * No 38 * + + - DCIS 
BRCA1 missense 
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C61G 14068 Yes C65 WT * No 32 3 - - + IDC 
C61G 19882 Yes C65 WT * No 29 3 - - - IDC 
E597K 98286 No C0 None * No 45 1 + + * IDC 
E736A 15102 No C0 None * No 44 * + + - DCIS 
I1275V 4061 No C0 WT * No 37 3 - - - IDC 
K1109N 0477a** No C0 None * No 35 * * * * DCIS 
K1109N 0477b** No C0 None * No 49 2 + + - IDC 
L1764P 4744 Yes C35 WT * No 32 3 - - + IDC 
P1637L 175158 Close C0 WT * No 47 * + + - IDC 
P1776H 154045 No C0 WT * No 48 3 + + - * 
P1776H 133886 No C0 WT * No 55 * * * * Unspecified 
P334H 34402 No C0 None * No 38 2 + + - IDC 
S127N 4060 No C0 V * No 38 * * * * IDC 
V1247I 11092 No C0 None * No 40 3 + + - IDC 
V1804D 16719 Yes C0 V * No 58 2 + - + IDC 
V1804D 73481 Yes C0 * * No 59 1 + + * IDC 
V772A 78081 No C0 WT * Yes 47 1 - - * IDC 
T1310K 176831 No C0 None * No 45 * * * * DCIS 
Y856H 1995 No C0 None * Yes 45 3 + + + DCIS 
Y856H 4294 No C0 None * Yes 47 * * * * DCIS 
BRCA2 truncating 
2041delA 46662 N/A N/A  None * N/A 34 3 + + - IDC 
3036del4 4208 N/A N/A U * N/A * 2 + + - IDC 
3036del4 4310 N/A N/A WT * N/A 36 3 + + + IDC 
3036del4 542 N/A N/A WT * N/A  43 * + + * IDC 
3972del4 5-077 N/A N/A WT * N/A * * + + * IDC 
4206ins4 26949 N/A N/A None * N/A 37 1 + + - LCIS 
4361del4 2609 N/A N/A WT * N/A * * - + - IDC 
5270delTG 169989 N/A N/A None * N/A 46 2 + - * IDC 
6174delT 4317 N/A N/A WT * N/A 46 3 - - - IDC 
6503delTT 35962 N/A N/A WT * N/A 46 2 + + + IDC 
7990del3ins2 15494 N/A N/A WT * N/A 41 3 + - - IDC 
8765delAG 5702 N/A N/A * * N/A 50 * - - * IDC 
8803delC 80659 N/A N/A None * N/A 36 * + + * Unspecified 
9481insA 94467 N/A N/A WT * N/A 64 2 + + + IDC 
Q321X 3-744 N/A N/A V * N/A * 4 + + - IDC 
S1882X 3553 N/A N/A WT * N/A 37 3 + + - IDC 
Y1894X 11008 N/A N/A WT * N/A 26 * + + - IDC 
BRCA2 intronic 
IVS13+5G>C 16004 N/A N/A WT * No 46 2 + + - IDC 
IVS23+9C>T 12673 N/A N/A WT No No 40 2 + + + IDC 
IVS8-12delTA 64703 N/A N/A None No No 44 1 + + - IDC 
BRCA2 Missense 
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A1170V 143226 No C0 * * No 52 3 - + + IDC 
A2351G 2664 No C0 None * No 61 3 - - - IDC 
D1352Y 11193 No C0 WT * No 47 2 + + - IDC 
E2856A 5047 Yes C0 V * No 45 2 + + - IDC 
H1966Y 46345 No C0 V * No 44 3 - - - IDC 
I2285V 4112 No C25 V * No * 2 + + + IDC 
K1434I 34415 No C15 None * No 58 * + - * DCIS 
L2106P 161491 No C0 None * No 57 3 + + - IDC 
L929S 14388 No C0 None * Yes 37 2 + + - IDC 
M2676T 565 Yes C0 None * No 49 * + * * IDC 
N1878K 14573a** No C0 V * No 63 1 + - - IDC 
N1878K 14573b** No C0 V * No 67 2 + + - IDC 
N517S 11859 No C0 None * No 45 1 + + * IDC 
N588D 0772 No C0 WT * No 56 2 + + + IDC 
N987I 14388 No C0 None * Yes 37 2 + + - IDC 
P1819S 4146 No C0 None * No 57 1 + + - IDC 
P655R 11631 No C0 None * No 38 3 + + - IDC 
R2034C 2098 No C0 None * Yes 75 3 - - + IDC 
R2418G 26664 Yes C0 None * No 61 2 + + - IDC 
R2502H 98245 Yes C0 None * No 58 3 + + - IDC 
R2973C 2382 Yes C25 WT * No 52 2 + + - IDC 
S1424C 155088 No C0 None * No 55 * * * * * 
S2483N 25006 Yes C0 None * No 48 1 + + - IDC 
S384F 6996 No C0 WT * Yes 49 2 + + + IDC 
T2681R 25705 Yes C0 WT * No 34 3 - - - IDC 
T3211K 59457 Yes C0 None * No 52 3 - - - * 
Y42C 4620 No C0 V * No 40 * - - - IDC 
@Change predicted to affect splicing by splice finder 
54Change shown to affect splicing by others 
**Individual has bilateral breast cancer and both tumors were included 
Abbreviations: *, No data; N/A, not applicable; WT, loss of wild type allele; V, loss of variant allele; U, uncertain loss; +, positive;  
-, negative; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; DCIS, ductal carcinoma in situ; LCIS, lobular carcinoma in 
situ 
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   Table 5: Ovarian tumor characteristics 
Sequence Change Sample 
Conserved 
domain LOH 
A- GVGD 
Class 
In 
Trans Stage Grade Age Histology 
BRCA1 Truncating 
1135insA 24127 N/A WT N/A  No * 3C 59 Papillary Serous 
262delT 0690 N/A WT N/A  No * 3C 63 Endometroid 
3600del11 10945 N/A WT N/A  No * 3 41 Serous 
BRCA1 Missense 
P334L 6167 No WT C0 Yes * * 39 Unspecified 
BRCA2 Truncating 
6307insA 4945 N/A none N/A  N/A * * * Unspecified 
7297delCT 0947 N/A none N/A  N/A * 3C 22 Serous 
7990del3ins2 540 N/A none N/A  N/A * * 46 Unspecified 
9481insA 23722 N/A WT N/A  N/A * 3C 59 Papillary Serous  
BRCA2 Missense 
A1170V 97594 No V C0 No * * 59 * 
D1420Y 0690 No none C15 Yes * 3C 63 Endometrioid 
L2721H 6167 Yes WT C25 No * * 39 Unspecified 
M784V 11073 No V C0 No 3C 3 45 Unspecified 
S1172L 5701 No none C15 No 3C * 58 Serous 
S326R 5701 No none C0 Yes 3C * 58 Serous 
V1643A 76049 No WT C0 No PT3C * 50 Serous 
   Abbreviations: N/A, not applicable; *, no data; LOH, loss of heterozygosity; WT, loss of wildtype allele; V, loss of  
   variant or mutant allele 
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                                               1     2    3     4    5     6    7    1     2    3    4     5    6     7 
Figure 4: BRCA1 Unmethylated and Methylated PCR Products.  The primers for unmethylated DNA yielded 
bands (86 bp) for all samples except the negative controls of dH2O and Non-Bisulfite treated Control DNA.  
The primers for methylated DNA yielded a band (182 bp) only for the Methylated Bisulfite treated Control 
DNA. 
 
 
Unmethylated Methylated 
1 = dH2O 
2-4 = Tumor Bisulfite treated DNA 
5 = Non-Bisulfite treated Control 
6 = Unmethylated Bisulfite treated Control 
7 = Methylated Bisulfite treated Control 
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                                      1    2    3   4    5   6   7    8   9   10 11  12  13 14  15  16 
Figure 5: BRCA2 Unmethylated PCR Products.  The primers for unmethylated DNA yielded bands (145 bp) for 
nine samples of Tumor Bisulfite treated DNA and the Unmethylated Bisulfite treated Control DNA.  Bands 
were absent for dH2O, three samples of Tumor Bisulfite treated DNA, Non-Bisulfite treated Control DNA, and 
the Methylated Bisulfite treated Control DNA. 
 
 
 
 
 
 
 
 
 
                               1    2    3   4    5   6   7    8   9   10 11  12 13  14  15  16 
Figure 6: BRCA2 Methylated PCR Products.  The primers for methylated DNA yielded a band (180 bp) only 
for the Methylated Bisulfite treated Control DNA.  Bands were absent for all other samples.
Unmethylated 
Methylated 
1 = dH2O 
2-13 = Tumor Bisulfite treated DNA 
14 = Non-Bisulfite treated Control 
15 = Unmethylated Bisulfite treated Control 
16 = Methylated Bisulfite treated Control 
1 = dH2O 
2-13 = Tumor Bisulfite treated DNA 
14 = Non-Bisulfite treated Control 
15 = Unmethylated Bisulfite treated Control 
16 = Methylated Bisulfite treated Control 
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Figure 7: Splice Site Analysis of IVS5-11G>T.  The RT-PCR Products were amplified with primers that 
annealed to the two flanking exons (exons 5 and 7).  Aberrant splicing was observed in the Tumor cDNA as it 
produced two bands, which differed from the one band (232 bp) produced in eleven other wildtype cDNA 
controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Splice Site Analysis of IVS5-11G>T.  The RT-PCR Products were amplified with primers that 
annealed to one flanking exon (exon 5) and the causal exon (exon 6).  Aberrant splicing was observed in the 
Tumor cDNA as it produced two bands, which differed from the one band (132 bp) produced in eleven other 
wildtype cDNA controls.
Wildtype Controls Tumor 
cDNA 
Wildtype Controls Tumor 
cDNA 
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Table 6: Prediction of deleterious status for BRCA1 and BRCA2 breast tumors 
Sequence 
Change Sample 
 
 
LOH 
 
 
A-GVGD/ 
Mutation Splice  
In 
Trans Age  
Triple 
Neg ER PR 
 
 
 
HER
 
 
Grade 
ER 
 
 
 
Grade
 
 
 
HP 
 
 
 
Odds 
Odds  
no  
LOH 
 
 
 
Int 
BRCA1 Truncating 
1135insA# 1463 5.26 1000 1 1 9.65 5 1 1 1 1 1.97 1 4.9x105 9.5x104 D 
1240delC 0409 5.26 1000 1 1 9.65 5 1 1 1 1 0.55 1 1.4x105 2.6x104 D 
1294del40 4439 5.26 1000 1 1 1 1 1 2.29 1 4.1 1 1 4.9x104 9389 D 
1294del40 127345 5.26 1000 1 1 3.4 1 1 2.29 0.15 4.1 1 1 2.5x104 4788 D 
1294del40 78081+ 5.26 1000 1 1 1.67 1 1 2.29 1 0.2 1 1 4023 765 DS 
1294del40 169184 5.26 1000 1 1 9.65 5 1 1 1 1 1 1 2.5x105 4.8x104 D 
1294del40 Combo 765.5 1000 1 1 9.65 5 1 11.53 0.15 3.362 1 1 2.1x108 2.8x105 D 
1547del10 21538 5.26 1000 1 1 9.65 1 1 2.29 0.15 4.1 1 1 7.1x104 1.4x104 D 
1623del5 71759 5.26 1000 1 1 9.65 1 3.2 2.29 0.15 1 1 1 3.1x104 5834 D 
1675delA 10950 5.26 1000 1 1 9.65 1 1 2.29 1 4.1 1 1 4.8x105 9x104 D 
1793delA 12313 5.26 1000 1 1 9.65 5 1 1 1 1 1.97 1 4.9x105 9.5x104 D 
187delAG 45251a* 5.26 1000 1 1 9.65 1 1 2.29 0.15 4.1 1 1 7.1x104 1.4x104 D 
187delAG 45251b* 5.26 1000 1 1 9.65 5 1 1 1 1 1.97 1 4.9x105 9.5x104 D 
187delAG 5042 5.26 1000 1 1 9.65 5 1 1 1 1 1.97 1 4.9x105 9.5x104 D 
187delAG Combo 145.53 1000 1 1 9.65 25 1 2.29 0.15 4.1 3.88 1 1.9x108 1.3x106 D 
2530delAG 458 5.26 1000 1 1 9.65 5 1 1 1 1 0.55 1 1.4x105 2.7x104 D 
2553delC 4724 5.26 1000 1 1 15.3 1 1 1 1 4.1 1 1 3.3x105 6.3x104 D 
2576delC 61933 5.26 1000 1 1 1.67 5 1 1 1 1 1.97 1 8.7x104 1.6x104 D 
2576delC 175158 5.26 1000 1 1 3.4 1 0.23 0.31 1.2 1 1 1 1530 291 DS 
2576delC Combo 27.66 1000 1 1 3.4 5 0.23 0.31 1.2 1 1.97 1 7.9x104 2865 D 
2800delAA 24042a* 5.26 1000 1 1 9.65 1 1 1 1 1 1.97 1 9.9x104 1.9x104 D 
2800delAA 24042b* 0.285 1000 1 1 3.4 5 1 1 1 1 0.55 1 2665 9350 D 
2800delAA Combo 1.499 1000 1 1 9.65 5 1 1 1 1 1.08 1 7.8x104 5.2x104 D 
3118delA 11984 0.0667 1000 1 1 9.65 5 1 1 1 1 1.97 1 6340 9.5x104 D 
3600del11 34406 5.26 1000 1 1 9.65 5 1 1 1 1 0.55 1 1.4x105 2.7x104 D 
5382insC 20758 5.26 1000 1 1 1.25 1 1 2.29 1 4.1 1 1 6.2x104 1.2x104 D 
E143X 34642 5.26 1000 1 1 9.65 5 1 1 1 1 1.97 1 4.9x105 9.5x104 D 
Q563X 61051 5.26 1000 1 1 3.4 1 0.23 2.29 1.2 1 1.97 1 2.2x104 4233 D 
S868X 176811 0.285 1000 1 1 1.25 1 0.23 0.31 1.2 1 1.97 1 60 210 U 
Q1408X 34642 0.285 1000 1 1 15.3 5 1 1 1 1 1 1 4.9x104 1.8x105 D 
BRCA1 Splicing                 
IVS4-1 G>T 2364a* 5.26 1 1000 1 3.4 1 1 2.29 1 4.1 1 1 1.7x105 3.2x104 D 
IVS4-1 G>T 2364b* 5.26 1 1000 1 3.4 1 0.23 0.31 1.2 1 0.11 1 168 32 U 
 
IVS4-1 G>T Combo 27.66 1 1000 1 3.4 1 0.23 0.71 
 
1.2 
 
4.1 
 
0.11 1 
 
8314 300 
DS
55 
IVS13+1 G>A 98453 0.285 1 1000 1 3.4 5 1 1 1 1 0.55 1 2665 9350 D10 
IVS15+1 G>A 2-112-140 5.26 1 1000 1 1 1 1 2.29 1 4.1 1 1 4.9x104 9389 D10 
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IVS5-11 T>G 45949 5.26 1 1000 1 1.67 5 1 1 1 1 0.55 4.3 1x105 1.9x104 D56 
BRCA1 intronic 
IVS12+10G>C 78081+ 0.285 1 1 1 1.67 1 1 2.29 1 0.2 1 1 0.218 0.765 U 
IVS20-14C>G 168788 0.285 1 0.01 1 9.65 1 0.23 0.31 1.2 1 1.97 1 0.0045 0.0162 NS 
IVS2-14C>T 64703 0.0667 1 0.01 1 3.4 1 1 0.31 1.2 1 0.11 1 0.0009 0.001 N 
IVS2-6T>C 15007 0.285 1 1 1 9.65 1 0.23 0.31 1.2 1 1 1 0.235 0.826 U 
BRCA1 missense 
C61G 14068 5.26 4.26 1 1 9.65 1 1 2.29 0.15 4.1 1 1 304 58 U 
C61G 19882 5.26 4.26 1 1 15.3 5 1 1 1 1 1.97 1 3377 642 DS 
C61G Combo 27.66 4.26 1 1 15.3 5 1 2.29 0.15 4.1 1.97 1 2.5x104 904 DS 
E597K 98286 0.285 0.01 1 1 3.4 1 0.23 0.31 1 1 0.11 1 7.6x10-5 0.00027 N10 
E736A 15102 0.285 0.01 1 1 3.4 1 0.23 0.31 1.2 1 1 1 0.00008 0.0029 N 
I1275V 4061 5.26 0.01 1 1 9.65 5 1 1 1 1 1.97 1 4.99 0.95 U10 
K1109N 0477a* 0.285 0.01 1 1 9.65 1 1 1 1 1 1 1 0.028 0.097 U 
K1109N 0477b* 1 0.01 1 1 3.4 1 1 2.29 1.2 0.37 1 1 0.092 0.035 U 
K1109N Combo 0.285 0.01 1 1 9.65 1 1 2.29 1.2 0.37 1 1 0.074 0.098 U10 
 
L1764P 4744 5.26 1.5 1 1 9.65 1 1 2.29 
 
0.15 
 
4.1 
 
1 1 
 
107 20.4 
U10
,59 
P1637L 175158 5.26 0.01 1 1 3.4 1 0.23 0.31 1.2 1 1 1 0.015 0.0029 N 
P1776H 154045 5.26 0.01 1 1 3.4 1 0.23 0.31 1.2 1 1.97 1 0.030 0.057 U 
P1776H 133886 5.26 0.01 1 1 1.67 1 1 1 1 1 1 1 0.088 0.017 U 
P1776H Combo 145.5 0.01 1 1 3.4 1 0.23 0.31 1.2 1 1.97 1 0.159 0.006 N 
P334H 34402 0.285 0.01 1 1 9.65 1 1 0.31 1.2 0.37 1 1 0.003 0.01 N 
S127N 4060 0.0667 0.01 1 1 9.65 1 1 1 1 1 1 1 0.0064 0.097 NS 
T1310K 176831 0.286 0.01 1 1 3.4 1 1 1 1 1 1 1 0.0097 0.034 NS 
V1247I 11092 0.285 0.01 1 1 3.4 1 0.23 0.31 1.2 1 1.97 1 0.0016 0.0057 N10 
V1804D 16719 0.0667 0.01 1 1 1.67 1 1 2.29 0.15 0.37 1 1 0.00014 0.014 NS 
V1804D 73481 1 0.01 1 1 1.67 1 1 0.31 1 0.067 1 1 0.00034 0.00034 N 
V1804D Combo 0.0667 0.01 1 1 1.67 1 1 0.71 0.15 0.025 1 1 2.9x10-6 4.4x10-5 N10 
V772A 78081+ 5.26 0.01 1 0.0001 3.4 1 1 2.29 1 0.2 1 1 8.2x10-6 1.6x10-6 N8 
Y856H 1995 0.285 0.01 1 0.0001 3.4 1 0.23 0.31 0.15 1 1.97 1 2x10-8 7x10-8 N 
Y856H 4294 0.285 0.01 1 0.0001 3.4 1 1 1 1 1 1 1 9x10-7 3x10-6 N 
Y856H Combo 0.08 0.01 
 
1 
 
0.0001 1 1 0.23 0.31 
 
0.15 
 
1 
 
1.97 
 
1 
 
5.7x10-9 7x10-8 
N8,
56 
BRCA2 truncating 
2041delA 46662 0.428 1000 1 1 4.97 1 1 1 1.2 2.2 1 1 5616 1.3x104 D 
3036del4 4208 1 1000 1 1 1 1 1 1 1.2 1.5 1 1 1800 1800 D 
3036del4 4310 4.6 1000 1 1 4.97 1 1 1 0.15 2.2 1 1 7544 1640 D 
3036del4 542 4.6 1000 1 1 2.89 1 1 1 1 1 1 1 1.3x104 2890 D 
3036del4 Combo 21.16 1000 1 1 2.89 1 1 1 0.18 3.3 1 1 3.6x104 1717 D 
3972del4 5-077 4.6 1000 1 1 1 1 1 1 1 1 1 1 4600 1000 D 
4206ins4 26949 0.428 1000 1 1 4.97 1 1 1 1.2 0.23 1 1 587 1371 D 
4361del4 2609 4.6 1000 1 1 1 1 1 1 1.2 1 1 1 5520 1200 D 
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5270delTG 169989 0.428 1000 1 1 2.89 1 1 1 1 1.5 1 1 1855 4335 D 
6174delT 4317 4.6 1000 1 1 2.89 1 1 1 1.2 1 1.3 1 2.1x104 4508 D 
6503delTT 35962 4.6 1000 1 1 2.89 1 1 1 0.15 1.5 1 1 2991 650 DS 
7990del3ins2# 15494 4.6 1000 1 1 2.89 1 1 1 1.2 2.2 1 1 3.5x104 7630 D 
8765delAG 5702 0.428 1000 1 1 2.07 1 1 1 1 1 1 1 886 2070 D 
8803delC 80659 0.428 1000 1 1 4.97 1 1 1 1 1 1 1 2127 4970 D 
9481insA 94467 4.6 1000 1 1 1.55 1 1 1 0.15 1.5 1 1 1604 349 DS 
Q321X 3-744 0.0667 1000 1 1 1 1 1 1 1.2 2.2 1 1 176 2640 D 
S1882X 3553 4.6 1000 1 1 4.97 1 1 1 1.2 2.2 1 1 6x104 1.3x104 D 
Y1894X 11008 4.6 1000 1 1 4.97 1 1 1 1.2 1 1 1 2.6x104 5652 D 
BRCA2 Intronic 
IVS13+5G>C 16004 4.6 1 1 1 2.89 1 1 1 1.2 1.5 1 1 23.93 5.2 U 
IVS23+9C>T 12673 4.6 1 0.01 1 2.89 1 1 1 0.15 1.5 1 1 0.03 0.0065 N 
IVS8-12delTA 64703 0.428 1 0.01 1 2.89 1 1 1 1.2 0.23 1 1 0.003 0.008 N 
BRCA2 Missense 
A1170V# 143226 1 0.01 1 1 2.07 1 1 1 0.15 1 1.3 1 0.027 0.027 U 
A2351G 2664 0.428 0.01 1 1 1.55 1 1 1 1.2 1 1.3 1 0.010 0.024 NS 
D1352Y 11193 4.6 0.01 1 1 2.89 1 1 1 1.2 1.5 1 1 0.239 0.05 U 
E2856A 5047 0.0667 0.01 
 
1 
 
1 2.89 1 1 1 
 
1.2 
 
1.5 
 
1 
 
1 
 
0.0034 0.52 
NS
3 
H1966Y 46345 0.0667 0.01 1 1 2.89 1 1 1 1.2 1 1.3 1 0.003 0.045 NS 
I2285V 4112 0.0667 0.01 1 1 1 1 1 1 0.15 1.5 1 1 0.001 0.002 N10 
K1434I 34415 0.428 0.01 1 1 2.07 1 1 1 1 1 1 1 0.009 0.027 NS 
L2106P 161491 0.428 0.01 1 1 2.07 1 1 1 1.2 2.2 1 1 0.023 0.054 U 
L929S 14388** 0.428 0.01 1 0.001 4.97 1 1 1 1.2 1.5 1 1 3.8x10-5 8.9x10-5 N60 
M2676T 565 0.428 0.01 1 1 1 1 1 1 1 1 1 1 0.012 0.029 U 
N1878K 14573a* 0.0667 0.01 1 1 1.55 1 1 1 1.2 0.23 1 1 0.0003 0.004 N 
N1878K 14573b* 0.0667 0.01 1 1 1.55 1 1 1 1.2 1.5 1 1 0.002 0.028 NS 
N1878K Combo 0.0045 0.01 1 1 1.55 1 1 1 1.44 0.345 1 1 3.4x10-5 0.008 N 
N517S 11859 0.428 0.01 1 1 2.89 1 1 1 1 0.23 1 1 0.003 0.007 N 
N588D 0772 4.6 0.01 1 1 2.07 1 1 1 0.15 1.5 1 1 0.02 0.005 N 
N987I 14388** 0.428 0.01 1 0.001 4.97 1 1 1 1.2 1.5 1 1 3.8x10-5 8.9x10-5 N60 
P1819S 4146 0.428 0.01 1 1 2.07 1 1 1 1.2 0.23 1 1 0.002 0.006 N10 
P655R 11631 0.428 0.01 1 1 4.97 1 1 1 1.2 2.2 1 1 0.056 0.131 U 
R2034C 2098 0.428 0.01 1 0.001 1.55 1 1 1 0.15 1 1.3 1 0.00001 2x10-6 N59 
R2418G 26664 0.428 0.01 1 1 1.55 1 1 1 1.2 1.5 1 1 0.011 0.028 U 
R2502H 98245 0.428 0.01 1 1 2.07 1 1 1 1.2 2.2 1 1 0.023 0.054 U 
R2973C 2382 4.6 0.41 1 1 2.07 1 1 1 1.2 1.5 1 1 7.03 1.53 U10 
S1424C 155088 0.428 0.01 1 1 2.07 1 1 1 1 1 1 1 0.009 0.008 N 
S2483N 25006 0.428 0.01 1 1 2.89 1 1 1 1.2 0.23 1 1 0.003 0.008 N 
S384F 6996 4.6 0.01 1 0.001 2.89 1 1 1 
 
0.15 
 
1.5 1 1 
 
2.9x10-5 6.5x10-6 
N3,
8,57 
T2681R 25705 4.6 0.01 1 1 4.97 1 1 1 1.2 1 1 1 0.274 0.059 U 
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T3211K 59457 0.428 0.01 1 1 2.07 1 1 1 1 1 1 1 0.009 0.021 NS 
Y42C 4620 0.0667 0.01 1 1 2.89 1 1 1 
1.2 1 
1 1 
 
0.002 0.035 
NS
3,12 
+Individual has both BRCA1 mutation and 2 BRCA1 variants 
*Individual has bilateral breast cancer, both tumors tested 
#Mutation also seen in a different individual with ovarian cancer 
**Individual has both BRCA2 L929S and N987I variants 
3,8,10,12,55,56,58-60Reclassified as neutral or deleterious by other studies 
Abbreviations: Combo, odds combined for all samples with variant; Triple Neg, triple negative; ER, estrogen receptor status; PR, 
progesterone receptor status; Her2, Her2 Neu status; HP, histopathology; D, Deleterious; N, neutral;  U, uncertain; DS, suspected 
deleterious; NS, suspected neutral; Int, Interpretation  
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   Table 7: Prediction of deleterious status in BRCA1 and BRCA2 ovarian tumors 
Sequence Change Sample LOH 
A-
GVGD/ 
Mutation Splice 
In 
Trans Stage Grade HP  Age  
 
 
Combined 
Odds 
Odds  
No  
LOH 
 
 
 
Interpretation 
BRCA1 Truncating 
1135insA+ 24127 4.45 1000 1 1 1 1.33 1.47 11.8 102662.3 23070.2 Deleterious 
262delT 0690# 4.45 1000 1 1 1 1.33 1 4.6 27225.1 6118 Deleterious 
3600del11 10945 4.45 1000 1 1 1 1.33 1.47 18 156603.51 35192 Deleterious 
BRCA1 Missense 
P334L 6167$ 4.45 0.01 1 0.0001 1 1 1 7.06 0.0000314 .0000071 Neutral10 
BRCA2 Truncating 
6307insA 4945 0.428 1000 1 1 1 1 1 1 428 1000 Deleterious 
7297delCT 0947 0.428 1000 1 1 1 1.61 1.76 0.52 630.65 1473.47 Deleterious 
7990del3ins2+ 540 0.428 1000 1 1 1 1 1 4.05 1733.4 4050 Deleterious 
9481insA 23722 4.6 1000 1 1 1 1.61 1.76 7.92 103233.72 22442.11 Deleterious 
BRCA2 Missense 
A1170V+ 97594 0.067 0.01 1 1 1 1 1 7.92 0.00528 0.0792 Neutral Suspected 
D1420Y 0690# 0.428 0.01 1 0.001 1 1.61 0.69 4.52 0.0000215 .00005 Neutral59 
L2721H 6167$ 4.6 0.41 1 1 1 1 1 0.52 0.9807 0.2132 Uncertain 
M784V 11073 0.067 0.01 1 1 2.05 1.61 1 4.05 0.009 0.1337 Neutral Suspected 
S1172L 5701** 0.428 0.01 1 1 2.05 1 1.76 7.92 0.1223 0.2857 Uncertain10 
S326R 5701** 0.428 0.01 1 0.001 2.05 1 1.76 7.92 0.000122 0.00028 Neutral 
V1643A 76049 4.6 0.01 1 1 2.05 1 1.76 7.92 1.3145 0.2858 Uncertain 
+Change also seen in a different individual with breast cancer 
#Individual carries both BRCA1 262delT and BRCA2 variant D1420Y 
$Individual carries both BRCA1 P334L and BRCA2 L2721H  
**Individual carries both BRCA2 S1172L and S326R 
10,59Reclassified as neutral by other studies 
Abbreviations:  LOH, loss of heterozygosity, A-GVGD, align-grantham variation, grantham deviation; HP, histopathology 
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Table 8: Variants of Uncertain Significance Reclassified as Neutral 
BRCA1 BRCA2 
IVS2-14C>T IVS8-12delTA 
IVS20-14C>G IVS23+9C>T 
S127N N517S 
P334H N588D 
E736A M784V 
T1310K A1170V 
P1637L S1424C 
P1776H K1434I 
 N1878K 
 H1966Y 
 A2351G 
 S2483N 
 T3211K 
  
 
 
 
 
 
 
 
